More News! 16 Sep 2022 Strategic collaboration for drug to treat NASH, obesity and diabetes announced …Dong-A will manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Korea. Cardiometabolic assets: a seismic shift for NeuroBo Gil Price, chief executive… September 16, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 19 Oct 2023 Biotech’s battle against NASH: The ongoing pursuit of an effective treatment …deliver novel medicines for people living with rare liver diseases – was a frontrunner in the race to bring the first ever NASH treatment to market. Its lead candidate for… October 19, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 HKUMed develops nanoparticle-based targeted drug delivery system …have been published in Nature Communications. Obesity is a major risk factor for a myriad of life-threatening chronic diseases such as diabetes, cardiovascular; and neurodegenerative disorders. TH is an ancient… February 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? …as well as in the field of cardiometabolic disorders. Its pact with South Korean biotech OliX Pharmaceuticals was in metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that occurs when… February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Partnership between Paradigm4 and Alnylam accelerates drug target discovery …obesity and metabolic syndrome – a condition impacting more than 20% of adults worldwide. Cardiometabolic disease These findings support the potential of INHBE as a novel therapeutic target to be… October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 13 Nov 2024 Sleep apnea: biotechs snore points in the therapeutic space …the National Council on Aging. Untreated forms of the disease can lead to heart, kidney, and metabolic health complications, which is why treating sleep apnea as early as possible is… November 13, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease …Medical, develops enzymes that can help to control the immune system for transplantations and the treatment of autoimmune diseases. The company’s lead candidate, IdeS, has been awarded the FDA’s Orphan… February 19, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2022 World’s first CAR-T for treatment of inflammatory disorders of the central nervous system approved in China …officer and chief medical officer of IASO Bio, said: “As one of the first companies to conduct research on CAR-T to treat autoimmune diseases worldwide, our BCMA CAR T-cell therapy… August 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2020 Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1B …brain to treat neurological diseases. As part of the deal, Evox will get €17.6M upfront to fund research for the next three years and Lilly will also invest €8.8M into… June 11, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 18 Nov 2022 How cardioids can usher in the next generation of drug discovery The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases… November 18, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Syncona to acquire Applied Genetic Technologies Corporation …clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal… October 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2020 BioMarin Partners Swiss Biotech to Develop Cardiac Gene Therapies US biotech BioMarin has partnered Swiss startup DiNAQOR to develop gene therapies to treat rare, inherited cardiac diseases. DiNAQOR will initially receive an upfront payment from BioMarin, followed by developmental,… May 7, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email